A 35-year-old man from Mumbai with a history of recurrent hemolytic episodes presents with acute jaundice, dark urine, and abdominal pain. Laboratory investigations reveal Hb 7.2 g/dL, reticulocyte count 18%, indirect bilirubin 5.8 mg/dL, haptoglobin <10 mg/dL, and LDH 1200 U/L. Direct antiglobulin test (DAT) is negative. Peripheral blood smear shows schistocytes and polychromasia. Renal function is normal (creatinine 0.9 mg/dL). What is the most appropriate immediate next step?

Explanation

## Clinical Diagnosis: Thrombotic Microangiopathy (TMA) This patient presents with **microangiopathic hemolytic anemia (MAHA)**, most consistent with **thrombotic thrombocytopenic purpura (TTP)** or hemolytic uremic syndrome (HUS): **Key Point:** The diagnostic pentad of TTP includes: 1. Microangiopathic hemolytic anemia (schistocytes, elevated LDH, low haptoglobin) 2. Thrombocytopenia (not mentioned but expected) 3. Neurological symptoms (not in this case, but can occur) 4. Renal dysfunction (absent here — argues against HUS) 5. Fever (not mentioned) ## Why This Is NOT AIHA | Feature | AIHA | MAHA/TTP | |---------|------|----------| | DAT | **Positive** | **Negative** | | Schistocytes | Absent | **Present** | | Haptoglobin | Low | **Very low (<10)** | | LDH | Mildly elevated | **Markedly elevated (>1000)** | | Mechanism | Antibody-mediated | Mechanical fragmentation | **High-Yield:** Negative DAT + schistocytes = **MAHA, not AIHA**. This is the critical discriminator. ## Management of TTP: Plasma Exchange ```mermaid flowchart TD A[Suspected TTP/MAHA]:::outcome --> B{DAT positive?}:::decision B -->|Yes| C[AIHA: Steroids]:::action B -->|No + Schistocytes| D[MAHA/TTP: Plasma Exchange]:::urgent D --> E[ADAMTS13 activity <10%?]:::decision E -->|Yes| F[Confirm TTP: Continue PE]:::action E -->|No| G[Consider HUS or other TMA]:::action ``` **Key Point:** Plasma exchange (PE) is the **life-saving emergency treatment** for TTP because it: 1. Removes circulating immune complexes and antibodies (in immune-mediated TTP) 2. Replenishes ADAMTS13 (the von Willebrand factor-cleaving protease) 3. Reduces platelet consumption and microthrombi formation 4. Mortality without PE: >90%; with PE: <10% **Clinical Pearl:** TTP is a **medical emergency**. Delays in plasma exchange of even 24 hours increase mortality. Do not wait for confirmatory tests (ADAMTS13 activity, thrombocyte count) — start PE immediately if TTP is suspected. ## Why Other Options Are Wrong | Option | Why Not | Consequence | |--------|---------|-------------| | Folic acid alone | Does not address the underlying microthrombi or platelet consumption. | Continued hemolysis and thrombotic complications | | FFP transfusion | May worsen TTP by adding more vWF and immune complexes. | Increased thrombosis and mortality | | Corticosteroids | Appropriate for AIHA, but this patient has MAHA (DAT-negative). | Delays definitive therapy; no benefit in TTP | **Warning:** ~~Transfusion of RBCs or FFP~~ is contraindicated in acute TTP — it worsens microthrombi formation. Only transfuse if Hb <5 g/dL and symptomatic, and only with careful volume control. **Mnemonic:** **MAHA = Mechanical hemolysis + Absent DAT = Microangiopathy** → Plasma Exchange